Patents by Inventor Steven D. Hughes

Steven D. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER USING IL-21
    Publication number: 20100316598
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: April 20, 2010
    Publication date: December 16, 2010
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • METHODS OF TREATING CANCER USING IL-21
    Publication number: 20100316599
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: April 28, 2010
    Publication date: December 16, 2010
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • METHODS OF TREATING CANCER USING IL-21
    Publication number: 20100316597
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: April 20, 2010
    Publication date: December 16, 2010
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • Human cytokine receptor
    Patent number: 7851594
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: December 14, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • METHODS OF TREATING CANCER USING IL-21
    Publication number: 20100310505
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: March 18, 2010
    Publication date: December 9, 2010
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • Human cytokine receptor
    Patent number: 7790851
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Anti-IL-TIF antibodies and methods of using in inflammation
    Patent number: 7718172
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: May 18, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Anti-IL-TIF antibodies
    Patent number: 7674461
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: March 9, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20090264624
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: May 4, 2009
    Publication date: October 22, 2009
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY
    Publication number: 20090087404
    Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
    Type: Application
    Filed: October 14, 2008
    Publication date: April 2, 2009
    Inventors: Wayne R. Kindsvogel, Steven D. Hughes, Richard D. Holly, Christopher H. Clegg, Donald C. Foster, Rebecca A. Johnson, Mark D. Heipel, Pallavur V. Sivakumar
  • ANTI-IL-TIF ANTIBODIES AND METHODS OF USING IN INFLAMMATION
    Publication number: 20090022723
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Application
    Filed: July 27, 2007
    Publication date: January 22, 2009
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20080247945
    Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
    Type: Application
    Filed: May 21, 2008
    Publication date: October 9, 2008
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20080214785
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: July 27, 2007
    Publication date: September 4, 2008
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
    Patent number: 7393684
    Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: July 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
  • Human cytokine receptor
    Patent number: 7265203
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: September 4, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Anti-IL-TIF antibodies and methods of making
    Patent number: 7265211
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: September 4, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Anti-IL-TIF antibodies and methods of using in inflammation
    Publication number: 20040023341
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Application
    Filed: March 24, 2003
    Publication date: February 5, 2004
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Methods of treating cancer using IL-21
    Publication number: 20040009150
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: June 6, 2003
    Publication date: January 15, 2004
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • Human cytokine receptor
    Publication number: 20030099608
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: March 22, 2002
    Publication date: May 29, 2003
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Transgenic rabbit that expresses a functional human lipoprotein (a)
    Patent number: 6512161
    Abstract: A transgenic rabbit which has in its genomic DNA sequences that encode apolipoprotein (a) and apolipoprotein B polypeptides which are capable of combining to produce lipoprotein (a), a process for creating such a rabbit, and the use of the rabbit to identify compounds which are effective in the treatment of human diseases which are associated with, induced and/or exacerbated by Lp(a) expression.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: January 28, 2003
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Didier Rouy, Nicolas Duverger, Florence Emmanuel, Patrice Denefle, Louis-Marie Houdebine, Celine Viglietta, Edward M. Rubin, Steven D. Hughes